$18.7B Gene Editing Market by 2030 CASGEVY First CRISPR therapy approved (Dec 2023) 47.6% CAGR Gene therapy market growth FDA 3.0 Accelerating genetic medicine approvals Prime Editing Search-and-replace DNA technology Vertex + CRISPR $11.1B partnership value $18.7B Gene Editing Market by 2030 CASGEVY First CRISPR therapy approved (Dec 2023) 47.6% CAGR Gene therapy market growth FDA 3.0 Accelerating genetic medicine approvals Prime Editing Search-and-replace DNA technology Vertex + CRISPR $11.1B partnership value
Precision Genome Engineering

The Future of Gene Editing Is Here

From CRISPR-Cas9 to prime editing, gene modification technologies are revolutionizing medicine. Correct genetic mutations, cure inherited diseases, and engineer next-generation cell therapies.

Acquire Domain Explore Technology
A T C G
$18.7B
Gene Editing Market 2030
47.6%
CAGR 2024-2030
90%+
On-Target Editing Efficiency
4
FDA-Approved Gene Therapies (2024)

Precision Editing Technologies

From cutting to writing - the evolution of genome engineering

✂

CRISPR-Cas9

The revolutionary molecular scissors that enabled precise DNA cutting. Nobel Prize-winning technology (2020) now powering approved therapies for sickle cell disease and beta thalassemia.

✎

Base Editing

Single-nucleotide precision without double-strand breaks. Directly converts one base pair to another. Beam Therapeutics advancing multiple clinical programs for genetic blood disorders.

🔎

Prime Editing

Search-and-replace DNA editing. Can make all 12 types of point mutations plus small insertions and deletions. Prime Medicine leading clinical development for this next-gen platform.

🔬

In Vivo Delivery

Lipid nanoparticles and AAV vectors delivering editors directly to tissues. Intellia's NTLA-2001 showed 87% transthyretin reduction with single IV dose in human trials.

🧬

Ex Vivo Cell Engineering

Edit cells outside the body, then return them to patients. Powers CAR-T therapies and CASGEVY for sickle cell. Enables quality control before administration.

🚀

Epigenome Editing

Regulate gene expression without changing DNA sequence. Reversible modifications using CRISPR-based activators and repressors. Chroma Medicine pioneering epigenetic therapies.

Gene Editing Leaders

Companies advancing the precision medicine revolution

Company Technology Lead Programs Status
CRISPR Therapeutics CRISPR-Cas9 CASGEVY (sickle cell, beta-thal) FDA Approved
Intellia Therapeutics In Vivo CRISPR NTLA-2001 (ATTR amyloidosis) Phase III
Beam Therapeutics Base Editing BEAM-101 (sickle cell) Phase I/II
Prime Medicine Prime Editing PM359 (chronic granulomatous) Phase I
Editas Medicine CRISPR-Cas12a EDIT-301 (sickle cell) Phase I/II
Verve Therapeutics Base Editing VERVE-101 (hypercholesterolemia) Phase I
Chroma Medicine Epigenome Editing Gene silencing platform Preclinical
Vertex Pharmaceuticals CRISPR Partner CASGEVY commercialization Commercial

Own the Gene Editing Brand

GeneEditing.app - Premium domain for the precision medicine era. Perfect for platforms, education, or therapeutic development.

Contact for Pricing
Acquire This Domain

Own Geneediting

This premium domain is available for acquisition. Perfect for companies, startups, or investors in this space.

Submit your inquiry below and we'll respond within 24 hours.